Who
Kevin M. Brennan
SVP, Finance and Accounting
Company insider
Files Form 4 as: SVP, Finance and Accounting, Xilio Therapeutics.
In numbers
- Trades disclosed
- 24
- Buys
- 0
- Sells
- 2
- Bought
- $0
- Sold
- $4,110
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 1 Apr 2023
- Last trade
- 2 Jan 2026
- Last filed
- 5 Jan 2026
Companies traded
Activity over time
1 Dec 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 2 Jan 2026filed 5 Jan 2026 | XLO Xilio TherapeuticsBiotechnology | SEC FORM 4 Sold | $1,1741,826 at $0.6432 | filing |
| 2 Jan 2026filed 5 Jan 2026 | XLO Xilio TherapeuticsBiotechnology | SEC FORM 4 Sold | $1,1691,826 at $0.64 | filing |
| 1 Jan 2026filed 5 Jan 2026 | XLO Xilio TherapeuticsBiotechnology | SEC FORM 4 Code M | —5,000 | filing |
| 1 Jan 2026filed 5 Jan 2026 | XLO Xilio Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,000 at $0.00 | filing |
| 1 Jan 2026filed 5 Jan 2026 | XLO Xilio Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,000 at $0.00 | filing |
| 1 Jan 2026filed 5 Jan 2026 | XLO Xilio TherapeuticsBiotechnology | SEC FORM 4 Code M | —5,000 | filing |
| 31 Dec 2025filed 5 Jan 2026 | XLO Xilio Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —95,221 at $0.00 | filing |
| 31 Dec 2025filed 5 Jan 2026 | XLO Xilio Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —95,221 at $0.00 | filing |
| 21 Nov 2025filed 25 Nov 2025 | XLO Xilio Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —131,700 at $0.00 | filing |
| 21 Nov 2025filed 25 Nov 2025 | XLO Xilio Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —55,000 | filing |
| 21 Nov 2025filed 25 Nov 2025 | XLO Xilio Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —55,000 | filing |
| 21 Nov 2025filed 25 Nov 2025 | XLO Xilio Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —25,000 | filing |
| 21 Nov 2025filed 25 Nov 2025 | XLO Xilio Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 | filing |
| 21 Nov 2025filed 25 Nov 2025 | XLO Xilio Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —20,000 | filing |
| 21 Nov 2025filed 25 Nov 2025 | XLO Xilio Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 | filing |
| 2 Jan 2025filed 3 Jan 2025 | XLO Xilio TherapeuticsBiotechnology | SEC FORM 4 Sold | $1,7671,803 at $0.98 | filing |
| 1 Jan 2025filed 3 Jan 2025 | XLO Xilio Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —5,000 at $0.00 | filing |
| 1 Jan 2025filed 3 Jan 2025 | XLO Xilio Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —60,000 at $0.00 | filing |
| 1 Jan 2025filed 3 Jan 2025 | XLO Xilio TherapeuticsBiotechnology | SEC FORM 4 Code M | —5,000 | filing |
| 1 Oct 2024filed 2 Oct 2024 | XLO Xilio Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —26,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.